Kristof Vercruysse on ”First in Human” Presented at ASH25
Kristof Vercruysse, CEO and Co-Founder at TargED Biopharmaceuticals, reposted from TargED Biopharmaceuticals on LinkedIn:
”Back in town from ASH25.
What a journey and emotional rollercoaster it has been the last days.
Thanks to the full TargED team to make the First in Human happen with positive results and looking forward for more to come.”
Quoting TargED Biopharmaceuticals‘s post:
”We are excited to announce positive results from a Phase 1 study for TargED’s lead investigational thrombolytic fusion protein, TGD001, in an oral presentation at ASH25 in Orlando, Florida today.
The first-in-human clinical trial demonstrated that TGD001 is safe and was well tolerated with no spontaneous bleeding events across four ascending dose cohorts.
TargED Biopharmaceuticals plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 as a potential treatment for patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
Read the full press release with detailed results.
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause